SCYNEXIS (SCYX) Stock: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$5.12
-0.25 (-4.66%)
âŧ
5d:
+16.63%
30d:
-1.92%
90d:
+8.25%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
30d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SCYX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SCYX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $5.12, which is considered slightly low relative to its 30-day fair value range of $4.46 to $5.28. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.2) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is in a strong uptrend. Immediate support is located at $4.27, while resistance sits at $5.51. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: SCYX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.33 (+609.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCYX is in a strong uptrend. Immediate support is located at $4.27, while resistance sits at $5.51. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: SCYX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.33 (+609.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.46 -
$5.28
Company Quality Score
48/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 609.6% below Wall St target ($36.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.46 -
$5.28
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.27
Resistance Level
$5.51
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.21
Wall Street Target
$36.33
(+609.6%)
Revenue Growth (YoY)
-82.8%
Profit Margin
-53.3%
PE vs Historical
-2.2 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: October 04, 2026 5:48 AM ET
Data refreshes hourly during market hours. Next update: 6:48 AM
Data refreshes hourly during market hours. Next update: 6:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
